Biodel Inc. to Present New Preclinical Glucagon Data During Corporate Overview at JMP Securities Healthcare Conference
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DANBURY, Conn., July 3, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) announced today that management will present new preclinical pharmacokinetic and pharmacodynamic data on its glucagon formulation intended for use in a novel auto-reconstitution device. Biodel's glucagon injection system is designed to improve on existing treatments for severe hypoglycemia. These data will be presented during a corporate overview of the Company on Tuesday, July 9, 2013 at 12:30 p.m. EDT at the Eighth Annual JMP Securities Healthcare Conference in New York City.
Help employers find you! Check out all the jobs and post your resume.
DANBURY, Conn., July 3, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) announced today that management will present new preclinical pharmacokinetic and pharmacodynamic data on its glucagon formulation intended for use in a novel auto-reconstitution device. Biodel's glucagon injection system is designed to improve on existing treatments for severe hypoglycemia. These data will be presented during a corporate overview of the Company on Tuesday, July 9, 2013 at 12:30 p.m. EDT at the Eighth Annual JMP Securities Healthcare Conference in New York City.
Help employers find you! Check out all the jobs and post your resume.